


PHARMACEUTICAL 2021

PLx Pharma Inc. Rank 270 of 409







PHARMACEUTICAL 2021

PLx Pharma Inc. Rank 270 of 409



The relative strengths and weaknesses of PLx Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLx Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of PLx Pharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is -235%, being 120% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	22,986
Cost of Goods Sold	0
Intangible Assets	2,061
Liabilities, Current	3,542
Liabilities, Non-Current	134
Other Assets	344
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	12,487
Other Net Income	-1,752
Property and Equipment	1,226
Research and Development	4,339
Revenues	30
Selling, General and Administrative Expense	9,151

Output Variable	Value in 1000 USD
Assets	26,617
Liabilities	16,164
Expenses	13,490
Stockholders Equity	10,453
Net Income	-15,211
Comprehensive Net Income	-15,211
Economic Capital Ratio	-235%